My weekly roundups of biomedical news tend to focus on stem cells, but I read more broadly so it’s not just stem cells but also CAR-T cells and a lot more this week. CAR-T cells as senolytics? A team led by Scott Lowe has a new intriguing paper in Nature on using CAR-T cells to […]
Weekly roundup: CAR-T cells, exosomes, trout cloning Read More »
The idea of testing stem cells for COVID-19 may be music to the ears of some folks as an opportunity, but to me from the beginning it sounded mostly like a spaghetti on the wall road to trouble. There is buzz out there that some kind of stem cells or other cells will help with
Field throws stem cells for COVID-19 like spaghetti on the wall Read More »
It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an
COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »
This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the last month. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm
FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36 Read More »
Today’s post includes a list of firms/products that have self-reported that they have received FDA regenerative medicine advanced therapy designation or RMAT. Sometimes people call these “r mat” with a space. I also include FDA data on RMAT submissions via an FDA RMAT resource page. At this point as of May 2025, I have found
Updated FDA granted RMAT List (130) Read More »
Over at the California Stem Cell Report, David Jensen is reporting on some good news from CIRM for California on the stem cell clinical trial front. Stem cell biotechs Asterias and Capricor have stem cell trials supported by 20+ million in CIRM funding each and have been hitting milestones. These trials are progressing and so far have good safety
Upbeat prospects for some California clinical trial efforts from CIRM Read More »
Every year I look into my stem cell crystal ball and make a top 10 list of stem cell predictions for the coming year. My predictions for 2015 will be coming up soon and I may bump them up to 20 predictions instead of 10 because there’s so much going on in the field. Stay
Stem cell crystal ball: how did my 2014 predictions fare? Read More »
What does the future hold for CIRM? I asked former CIRM Board Chair and Prop 71 leader, Robert Klein, about that and more in the interview below. He also says some particularly exciting clinical trial and other developments in the stem cell field are coming soon. What got you excited for the very first time
Interview with Robert Klein on CIRM’s Future Read More »